Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and  Etoposide: A Non–Cross-Resistant Schedule

Groen, Harry J.M.; Fokkema, Eelco; Biesma, Bonne; Kwa, Bibi; Putten, John W. G. van; Postmus, Pieter E.; Smit, Egbert F.

doi:10.1200/jco.1999.17.3.927

Cited by 95 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data differ from those reported by Groen et al (1999) who studied the same combination (AUC 7 carboplatin plus 175 mg/m 2 paclitaxel as 3-h infusion every 3 weeks) as second-line treatment in 34 SCLC patients, most of whom had responded to a previous CDE regimen. Groen and colleagues obtained an impressive 73.5% response rate (with 6% complete responses) and a median survival (3) 1 (2.1) Vomiting (2-3) 6 (12.5) Diarrhoea (2) 1 (2.1) Oral mucositis (2) 2 (4.2) Fatigue (2-3) 15 (31.3) Headache (grade 3) 1 (2.1) Allergy (1-2) 2 (4.2) Skin (1) 1 (2.1) Fever (1) 1 (2.1) Cardiac (1) 1 (2.1) Respiratory (1-2) 3 (6.3) Renal (1) 1 (2.1) Hepatic (4) 1 (2.1) Constipation (1) 6 (12.5) Peripheral neurotoxicity (1-2) 3 (6.3) Central nervous system (1) 1 (2.1) Hair loss (2-3) 20 (41.7) exceeding 7 months.…”

Section: Discussioncontrasting

confidence: 56%

See 1 more Smart Citation

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

Gridelli

Manzione

Perrone³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

A multicentre phase 2 trial (single-stage design) was undertaken to test the efficacy and toxicity of carboplatin (AUC 6 according to Calvert) plus paclitaxel (175 mg/m 2 3-h infusion) every 4 weeks in the first line treatment of patients affected by extensive small cell lung cancer. The primary end-point of the trial was the objective response rate. 31 objective responses among 50 patients were considered necessary to proceed to a phase 3 trial. 48 patients were enrolled (median age 59 years). Treatment was very well tolerated. 3 patients (6.2%) had a complete response and 23 (47.9%) a partial response, for an overall response rate of 54.2% (95% CI: 39.2–68.6) Median time to progression was 5.7 months (95% CI: 5.2–6.2). Median survival was 9.6 months (95% CI: 7.2–14.6), with a median follow-up time of alive patients of 12 months. At 1 year, the probability of being progression-free or alive was 0.16 and 0.43, respectively. In conclusion, carboplatin plus paclitaxel as given in the present study is very well tolerated but not sufficiently active to warrant phase 3 comparison with standard chemotherapy regimens. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

Section: Discussioncontrasting

confidence: 56%

“…Paclitaxel has been associated with either carboplatin or cisplatin and, in 3-drug regimens, with etoposide (Hainsworth et al, 1997;Glisson et al, 1999). Carboplatin plus paclitaxel has proved successful as second-line treatment (Groen et al, 1999). There are no studies on the first-line use of this combination.…”

mentioning

confidence: 99%

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

Gridelli

Manzione

Perrone³

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In currently open randomized trials in the United Kingdom, regimens in use as standard control regimens include ACE and PE by the Medical Research Council, and CAV/PE by the London Lung Cancer Group. In North America, PE is widely regarded as standard (Murray 1997), while ACE is considered standard by the European Organization for Research and Treatment of Cancer (Groen et al, 1999). The Textbook of Lung Cancer recently published by the International Association for the Study of Lung Cancer (IASLC) lists the following regimens as commonly used and, by implication, standard: PE, CAV, ACE, and CbE (Carney and Shepherd, 2000).…”

Section: Discussionmentioning

confidence: 99%

A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

Sambrook

Girling

2001

Br J Cancer

View full text Add to dashboard Cite

Many chemotherapy regimens are used for treating SCLC in the United Kingdom, but it is not known, in any detail, which regimens are used, by which specialists, for which types of patient. We conducted a survey among all medical and clinical oncologists, respiratory physicians and general physicians with respiratory interest in the United Kingdom to find out. The questionnaire asked for the number of SCLC patients treated annually; how many were given chemotherapy; the drugs, doses and schedules chosen according to prognostic group (as defined by the clinician); and the reasons for choice of regimen. 1214 questionnaires were sent out, and responses were received from 1070 (88%) clinicians; 266 (25%) of these treated SCLC with chemotherapy. Of 4674 patients given chemotherapy annually, 36% were given it by clinical oncologists, 30% by medical oncologists, 27% by respiratory physicians, and 7% by general physicians. In all, 34 regimens were reported with 151 different combinations of dose and schedule. In 2311 good prognosis patients, 23 regimens were used, the commonest being ACE (doxorubicin, cyclophosphamide, etoposide), ICbE (ifosfamide, carboplatin, etoposide), CAV (cyclophosphamide, doxorubicin, vincristine), CbE (carboplatin, etoposide), and PE (cisplatin, etoposide). In 1517 poor prognosis patients, 21 regimens were used, the commonest being CAV, EV (etoposide, vincristine), CbE, CAV alternating with PE, and oral etoposide. 452 patients were treated regardless of prognosis and for 219 no prognostic criteria were specified. The remaining 175 were given second-line chemotherapy or were given regimens chosen to avoid toxicity or because of intercurrent disease or other reasons. The main reasons affecting choice of regimen were routine local practice, patients' convenience, quality of life considerations, trial results and cost. The results show wide variation in routine practice and will be useful in reporting and planning clinical trials and in deciding on local treatment policies. © 2001 Cancer Research Campaign http://www.bjcancer.com

show abstract

“…Etoposide plus cisplatin, IP and AMR monotherapy have been demonstrated to be particularly effective in SCLC (18)(19)(20). A previous study indicated that solvent-based paclitaxel plus carboplatin may be active in SCLC that is refractory to the above-based regimens (21). Previous studies have reported that the clinical behavior and prognosis of LCNEC are similar to those of SCLC, and that SCLC-based regimens are effective in patients with LCNEC (22,23).…”

Section: A B Cmentioning

confidence: 92%

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Thymic large cell neuroendocrine carcinomas (LCNECs) are rare, and the optimal regimen for second and subsequent lines of chemotherapy for the treatment of LCNECs remains unknown. In the present case study, a 59-year-old male with post-operative recurrent thymic LCNEC was treated with nab-paclitaxel and carboplatin every 4 weeks as third-line chemotherapy, and a partial response was achieved following 4 cycles of this regimen. The patient developed grade 4 neutropenia and grade 3 leukopenia, but none of the other toxicities, including peripheral neuropathy, were severe. Therefore, the patient was able to tolerate this salvage chemotherapy. To the best of our knowledge, the present study is the first case demonstrating clinically meaningful antitumor activity by combination chemotherapy with carboplatin and nab-paclitaxel, resulting in a positive response in a patient with thymic LCNEC.

show abstract

Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule

Abstract: Second-line PC in CDE-resistant SCLC patients yields a high response rate and seems non-cross-resistant to CDE. Toxicity was mild in these poor-prognosis patients.

Cited by 95 publications

References 23 publications

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study

A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Contact Info

Product

Resources

About